The outcome of a positive Rituximab trial for ME/CFS – possibly, finally, an FDA approved drug, relief for many, acceptance for this disease, increased research funding – would have been spectacular but Dr. Mella reported this week in Norway that the trial failed.
We won’t exactly how it failed until next year but the failure almost certainly means that Rituximab will not be the next FDA approved drug for ME/CFS.
That doesn’t mean Rituximab’s role in ME/CFS is necessarily over, however, and the Rituximab saga has brought much to the ME/CFS field. Read more about it in a Simmaron Research Foundation sponsored blog:
Tell us how your coronavirus vaccination went and find out how other people with ME/CFS and/or FM fared with their coronavirus vaccination in Health Rising’s Coronavirus Vaccine Side Effects Poll.